MyoKardia Inc. will regain the global rights to certain heart disease medicines in its pipeline after the company and Sanofi decided not to extend a research collaboration that sunset Dec. 31, 2018.
The two companies formed a research partnership in 2014 to develop three MyoKardia programs for the treatment of hypertrophic cardiomyopathy and dilated cardiomyopathy, which are diseases of the heart muscles. French drugmaker Sanofi has paid about $230 million to Myokardia under the collaboration.
MyoKardia said in a Jan. 2 press release that Sanofi provided advanced notice of its intent to terminate the partnership at the end of the original term.
"We are grateful for Sanofi's support over the past four years in what was a highly productive relationship," said MyoKardia CEO Tassos Gianakakos.
Myokardia has now regained global rights to all products in its pipeline. The company expects an increase in research and development expenses following the termination of the Sanofi agreement. Results of a phase 2 study of one of the drug candidates, MYK-491, are expected by the end of the year.
Meanwhile, Sanofi granted worldwide rights of osanetant, a neurokinin-3 receptor for certain neuroendocrine-related disorders, to Acer Therapeutics Inc. The financial terms of the agreement were not disclosed.
Newton, Mass.-based Acer Therapeutics develops therapies to treat rare diseases with unmet medical needs.